The Role for PSMA-PET Imaging in Active Surveillance

Focusing on active surveillance of patients with prostate cancer, discussion centers around the role of PSMA-PET imaging and the implications of negative scans.

EP: 1.Overview of Advances in Imaging in Prostate Cancer

EP: 2.The Impact of PSMA-PET Imaging in Prostate Cancer

EP: 3.Identifying the Right Patient Population for PSMA-PET Imaging

EP: 4.PSMA-PET Imaging in the Biochemical Recurrence Setting

EP: 5.The Impact of PSMA-PET Imaging on Treatment Decisions

Now Viewing

EP: 6.The Role for PSMA-PET Imaging in Active Surveillance

EP: 7.When and How Often PSMA-PET Imaging Should be Used

EP: 8.Monitoring Treatment Response

EP: 9.Unmet Needs and Challenges in Imaging of Prostate Cancer

EP: 10.The Value of Multidisciplinary Care in PSMA-PET Imaging

EP: 11.Future Directions in PSMA-PET Imaging

EP: 12.PSMA-PET Imaging for Prostate Cancer: Perspectives From a Nuclear Radiologist

EP: 13.Similarities and Differences Among PSMA-PET Tracers

EP: 14.Tips for Improving the Interpretation and Reporting of PSMA-PET Imaging Results

Related Videos

Related Content

Advertisement

January 23rd 2025

Health-related QOL is comparable among ARPI regimens for CSPC

Hannah Clarke

At 25 weeks, FACT-P total score remained comparable between the arms.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

January 13th 2025

FDA accepts NDA for 3-month leuprolide mesylate formulation for advanced prostate cancer

Hannah Clarke

The PDUFA target action date has been set for August 29, 2025.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

January 7th 2025

Expanded indication sought for darolutamide in mHSPC in China

Hannah Clarke

The application is supported by data from the pivotal phase 3 ARANOTE trial.

January 1st 2025

2024 Urology Times pipeline report

Jason M. Broderick Hannah Clarke Brittany Lovely

Catch up on all the notable drug and device approvals in urology over the past year.

Related Content

Advertisement

January 23rd 2025

Health-related QOL is comparable among ARPI regimens for CSPC

Hannah Clarke

At 25 weeks, FACT-P total score remained comparable between the arms.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

January 13th 2025

FDA accepts NDA for 3-month leuprolide mesylate formulation for advanced prostate cancer

Hannah Clarke

The PDUFA target action date has been set for August 29, 2025.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

January 7th 2025

Expanded indication sought for darolutamide in mHSPC in China

Hannah Clarke

The application is supported by data from the pivotal phase 3 ARANOTE trial.

January 1st 2025

2024 Urology Times pipeline report

Jason M. Broderick Hannah Clarke Brittany Lovely

Catch up on all the notable drug and device approvals in urology over the past year.